Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Salestools Logo

Salestools

#1 AI-agent til salgsteams og Go-to-Market-teams. Sælg mere, hurtigere, med mindre indsats.

Produkt

  • AI-salgsagenter
  • Intent-data
  • Teknologidata
  • Besøgssporing
  • Co-Pilot
  • Socialt salg

Løsninger

  • Kundeservice
  • E-handel
  • SaaS
  • Enterprise
  • Lille virksomhed

Ressourcer

  • Rapporten
  • Dokumentation
  • API-reference
  • Hjælpecenter
  • Blog
  • Case-studier
  • Webinarer

Virksomhed

  • Om os
  • Karriere
  • Presse
  • Kontakt
  • Partnere

Vores lokationer

  • New York, HQ
  • Bukarest, AI-forskningslaboratorium
  • Zug, Schweiz

© 2025 Salestools. Alle rettigheder forbeholdes.

Datavilkår & sikkerhedPrivatlivspolitikServicevilkår
Alle systemer operationelle
Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Back to The Report
Biotech

Twist Bioscience

Twist Bioscience raises $200M Convertible Note at $4B valuation

$200M
Total Raised
Convertible Note
Latest Round
2013
Founded
600+
Employees
681 Gateway Boulevard, South San Francisco, CA 94080
Updated April 11, 2024
1 min read

Quick Facts

Valuation
$4B
Latest Round Size
$200M
Latest Round Date
April 2024

Twist Bioscience: Convertible Note Funding Round

Twist Bioscience has successfully raised $200M in Convertible Note funding, reaching a valuation of $4B.

Company Overview

Synthetic DNA manufacturing

Funding Details

The Convertible Note round was led by Temasek Holdings, with participation from Fidelity, Paladin Capital Group, Casdin Capital.

Company Information

  • Headquarters: 681 Gateway Boulevard, South San Francisco, CA 94080
  • Founded: 2013
  • Employees: 600+
  • Category: Biotech

Investment

Twist Bioscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Temasek Holdings: Verified investor in Convertible Note
  • Fidelity: Verified investor in Convertible Note
  • Paladin Capital Group: Verified investor in Convertible Note
  • Casdin Capital: Verified investor in Convertible Note

Key Investors

Temasek Holdings
Lead Investor
Verified investor in Convertible Note
Fidelity
Investor
Verified investor in Convertible Note
Paladin Capital Group
Investor
Verified investor in Convertible Note
Casdin Capital
Investor
Verified investor in Convertible Note

Topics

verified(3079)real-funding(3079)twist-biosciencebiotechconvertible-note681-gateway-boulevard

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M